Could a Weight-Loss drug boost brain function? new study investigates
NCT ID NCT06171152
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This study looks at whether liraglutide (Saxenda®), a drug used for weight loss, can improve a brain health marker called BDNF in people with multiple sclerosis, long-COVID, or acute leukemia (in remission) who also have obesity and cognitive issues like memory or concentration problems. About 30 participants will take the drug for 8 weeks, and researchers will measure changes in BDNF levels. The goal is to gather early information on whether this drug might protect the brain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.